Published in Oncoimmunology on January 01, 2013
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | NCT01103635
Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res (2013) 1.95
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Cancer Cell (2016) 1.47
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother (2013) 1.08
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01
Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol Res (2014) 0.97
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res (2014) 0.91
Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90
Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med (2015) 0.87
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol Cell Oncol (2015) 0.86
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer (2013) 0.83
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. Cancer Immunol Res (2015) 0.82
Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol (2015) 0.79
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res (2015) 0.78
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol (2014) 0.78
The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. BMC Cancer (2014) 0.78
Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates. J Immunol (2015) 0.77
Harnessing immune responses in the tumor microenvironment: all signals needed. Clin Cancer Res (2013) 0.77
Signaling by Antibodies: Recent Progress. Annu Rev Immunol (2017) 0.76
Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death. Mol Cancer (2014) 0.76
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer (2017) 0.75
Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther (2016) 0.75
Designing therapeutic cancer vaccines by mimicking viral infections. Cancer Immunol Immunother (2016) 0.75
CD40 therapy and surgery: a potential immunologic partnership. J Immunother (2013) 0.75
A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. Sci Rep (2017) 0.75
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther (2016) 0.75
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
CD40-CD40 ligand. J Leukoc Biol (2000) 6.28
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res (2003) 2.50
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther (2010) 1.94
Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res (2007) 1.75
Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol (2002) 1.19
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother (2011) 1.14
Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res (2007) 1.08
Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol (2000) 1.05
Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. PLoS One (2011) 0.94
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02
Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol (2007) 3.68
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res (2012) 3.36
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol (2003) 3.21
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med (2012) 3.15
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol (2008) 2.65
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol (2011) 2.46
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol (2006) 2.35
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res (2007) 2.25
CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med (2012) 2.22
Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy. Ann Thorac Surg (2002) 2.15
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res (2002) 2.05
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res (2011) 2.03
Notch signaling augments T cell responsiveness by enhancing CD25 expression. J Immunol (2003) 1.95
Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol (2004) 1.93
HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res (2005) 1.81
Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg (2011) 1.80
Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther (2012) 1.72
Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer (2003) 1.70
Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys (2003) 1.68
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg (2003) 1.66
Clinical trial resources on the internet must be designed to reach underrepresented minorities. Cancer J (2007) 1.56
Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int J Radiat Oncol Biol Phys (2007) 1.55
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol (2003) 1.50
Patient initiation of complementary and alternative medical therapies (CAM) following cancer diagnosis. Cancer J (2007) 1.50
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res (2007) 1.47
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res (2010) 1.42
Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies. Cancer Biol Ther (2009) 1.40
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg (2012) 1.39
Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One (2009) 1.37
A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin Cancer Res (2004) 1.37
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology (2013) 1.37
Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res (2003) 1.35
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.34
Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol (2003) 1.34
Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res (2008) 1.26
Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res (2012) 1.23
Skin-sparing mastectomy and immediate reconstruction is an acceptable treatment option for patients with high-risk breast carcinoma. Cancer (2005) 1.22
Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol (2006) 1.21
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res (2008) 1.21
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol (2014) 1.20
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol (2013) 1.19
A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res (2006) 1.19
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer (2012) 1.18
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun (2013) 1.17
Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer (2013) 1.16
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother (2012) 1.14
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol (2010) 1.11
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother (2012) 1.11
A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials. Clin Trials (2012) 1.10
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2014) 1.09
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J Transl Med (2009) 1.09
Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Res (2007) 1.08
Proceedings of the University of Pennsylvania annual conference on statistical issues in clinical trials: early, translational and proof of concept studies: the 'go/no go' decisions. Stat Med (2010) 1.08
Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunol Immunother (2009) 1.07
A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. J Thorac Oncol (2012) 1.04
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res (2003) 1.03
Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol (2013) 1.02
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother (2012) 1.02
Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol (2004) 1.02
EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys (2006) 1.01
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res (2013) 1.01
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin Cancer Res (2004) 1.01
Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle (2007) 1.01
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res (2014) 1.01
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res (2007) 1.01
Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol (2007) 1.01
ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res (2004) 1.00
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res (2009) 1.00
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med (2013) 0.99
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Cell Cycle (2009) 0.98
Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS One (2011) 0.97
The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet (2012) 0.97
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res (2014) 0.95
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother (2012) 0.94
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin Cancer Res (2005) 0.94
Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung (2004) 0.93
Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies. Clin Lung Cancer (2013) 0.93
c-Met expression in tall cell variant papillary carcinoma of the thyroid. Cancer (2003) 0.92
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol (2003) 0.92
Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol (2002) 0.91
The role of mTOR inhibitors for treatment of sarcomas. Curr Oncol Rep (2007) 0.91
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res (2007) 0.91